New Study: Probiotic DE111® Shown to Promote a Healthy Microbiome for Immune Support in Daycare-Attending Children

KENNESAW, GA (December 2, 2020) – Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus subtilis DE111® can modify the composition of the microbiome in preschool-aged children.

The study, “Daily intake of probiotic strain Bacillus subtilis DE111 supports a healthy microbiome in children attending day-care” published in Beneficial Microbes, is an IRB-approved, randomized, double-blind, placebo-controlled four-week trial involving 91 children aged 2 to 6. Results of the study showed that daily consumption of the probiotic strain Bacillus subtilis DE111 positively modulated the gut microbiome profile without changing the overall microbiome equilibrium.

After 8 weeks of daily probiotic consumption, the researchers observed an increase in alpha-diversity at the phylum level, suggesting an expanded functional diversity of the microbiome compared to that of the children in the placebo group. Specifically, there were 9 differentially abundant taxa at the genus level found in the probiotic group, six (of the phylum bacteroidetes) grew in abundance while three (of the phylum firmicutes) were reduced. The six taxa of bacteroidetes that flourished are involved in immune regulation and reduction of inflammation. This modulation of the firmicutes/bacteroidetes ratio of the microbiome in children taking B. subtilis DE111 is a positive indication for healthy gut function.

Overall, according to the researchers, these results suggest B. subtilis DE111 supports the maintenance of a healthy gut through subtle modulations of the microbiome with significant benefits in preschool aged children.

“On the dawn of a new highly modified school year where health takes center stage, this study is highly encouraging to formulate natural, safe products for young children to promote immunity and overall well-being so they can concentrate on learning,” said John Deaton, vice president of science and technology at Deerland. “Focusing on supporting a healthy microbiome will result in more robust and effective immunity as children get older.”

Deerland Probiotics & Enzymes, based in Kennesaw, Ga., specializes in developing science-backed solutions that benefit microbiome health, using probiotic, prebiotic and enzyme technology.  The company offers a line of unique, clinically validated branded products, including DE111®, PreforPro®, ProHydrolase®, Solarplast®, Glutalytic® and Bifolac® probiotic strains.  Deerland collaborates with customers to develop innovative and often proprietary solutions in the dietary supplement, food and beverage, sports nutrition, and companion animal markets. In addition to branded ingredients and customized formulations, Deerland offers full turnkey products for private label through its YourBrand® portfolio.  The company’s manufacturing services include bulk blends, capsules, stick packs and tablets, as well as bottling and labeling. To contact Deerland Probiotics & Enzymes, call 800.697.8179 or visit www.deerland.com.

Follow us on social media for the latest updates in B2B!

Image

Latest

visitor management solution
Reinventing Visitor Management Solution with Symmetry GUEST
April 2, 2025

In an age where speed and security are paramount, the traditional paper logbook is becoming a relic of the past. AMAG Technology’s Symmetry Guest system offers a modern, digital solution that redefines the way organizations welcome and manage visitors. Gone are the days of long lines and confusion at the front desk—Symmetry Guest empowers hosts…

Read More
AMAG
Driven by Customers, Defined by Innovation: Inside AMAG’s Customer-Obsessed Approach
April 2, 2025

AMAG Technology continues to strengthen its customer-obsessed culture by actively listening to both internal and external voices. As shared by Kyle Gordon, Executive Vice President of Global Sales, Marketing, & Commercial Excellence, the company is focused on improving processes, responding with speed, and driving innovation—while honoring its legacy and delivering unique value within the industry.

Read More
biotech
Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation
April 2, 2025

As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion…

Read More
AMAG Technology
AMAG Technology Drives Positive Change, Product Innovation, and Stronger Partnerships with the Customer in Mind
April 2, 2025

At AMAG Technology, customer obsession is at the heart of everything the company does. Customer Relationship Manager Aimee Walsh shares how AMAG embraces positive change, enhances its products, and strengthens partnerships—all with the customer in mind. Her insights reflect AMAG’s ongoing commitment to evolving alongside customer needs and delivering meaningful solutions.

Read More